TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients
ConditionAsthma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorChiesi Poland Sp. z o.o.
About this trial
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.
Eligibility criteria
Qualifiers
Patients ≥ 18 years of age,
Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,
Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Trimbow
Treatment groups
No treatment groups listed
Sponsors and collaborators
Chiesi Poland Sp. z o.o.
Lead sponsor
Gesellschaft für Therapieforschung mbH
Collaborator
Source ClinicalTrials.gov